YOU ARE HERE: LAT HomeCollectionsOsteoporosis


May 18, 2002 | Bloomberg News
Celltech Group will work with Amgen Inc. on treatments for osteoporosis, a loss of bone density that can lead to fractures in elderly patients. Amgen gets marketing rights to Celltech drugs that target a protein linked to the illness, said Peter Allen, Celltech's finance director. Celltech will pay some costs until the end of Phase II tests and may opt to get some European rights. Shares of Celltech, Britain's largest biotechnology company, rose 55 cents to $16.85 on the NYSE.
A family of drugs already widely used to reduce cholesterol may provide the first effective treatment for osteoporosis, the bone-thinning disease that affects an estimated 28 million Americans. Unlike existing treatments, which merely slow or delay bone thinning, the drugs, called statins, actually increase bone density, Texas researchers report in today's Science.
March 6, 1989 | From Times staff and wire service reports
Daughters of women with osteoporosis appear to be at increased risk of developing the bone-thinning disease, Australian researchers reported last week. Dr. Ego Seeman and his colleagues at the Austin Hospital in Melbourne compared 32 women whose mothers had osteoporosis to 22 women whose mothers did not have the disease, which affects roughly 20 million Americans.
September 12, 1996 | From Times staff and wire reports
Fosamax, the first drug developed in 20 years to treat osteoporosis, also prevents the bone-thinning disease, according to a report presented Wednesday at a meeting of the American Society for Bone and Mineral Research. The two-year study, led by Dr. Michael McClung of the Oregon Osteoporosis Center in Portland, involved 1,609 women ages 45 to 59 who had been through menopause but had not suffered any fractures. The results showed that women taking Fosamax had a 3.
July 17, 2000 | From Washington Post
Women who take bone-preserving prescription drugs to help reduce their risk of osteoporosis are overlooking an important ingredient: calcium. Seven out of every 10 women who use one of the three top osteoporosis medications--Fosamax, Evista and Miacalcin Nasal Spray--fail to take bone-building calcium, according to a one-year survey of 3,442 physicians completed in April 2000.
August 25, 1995 | Times Wire Services
The Food and Drug Administration has approved an easier way for some women with osteoporosis to take their medicine. The best treatment is the hormone estrogen, but many women suffer side effects, including a possibly higher risk of certain cancers. For those women, the only alternative has been injections of the hormone calcitonin, which is derived from salmon. The FDA recently approved a version of calcitonin in an easier-to-use nasal spray, called Miacalcin.
October 25, 2002 | From Associated Press
A compound that works like estrogen, but with none of the side effects, has been found to prevent brittle bone disease in mice. The discovery may offer an alternative for women who stopped hormone replacement therapy because of the risks of cancer and heart disease. In a study appearing today in the journal Science, researchers say experiments with the compound estren increased bone density and strength in mice that had been surgically altered to mimic menopause.
Last week the Food and Drug Administration approved the first non-hormonal treatment of osteoporosis, Fosamax. With other medications on the horizon, an emerging issue is how to make the best use of bone mineral density testing, which can diagnose osteoporosis or even a woman's risk for it. Here, a closer look at osteoporosis. * Most women know that they should have a mammogram and Pap smear at regular intervals.
June 6, 1988 | From Times staff and wire reports
Younger women taking a commonly prescribed thyroid hormone may be at increased risk for bone-thinning osteoporosis if they are treated with too high a dose for a long period of time.
November 4, 1987 | THOMAS H. MAUGH II, Times Science Writer
Boron, a trace element not previously known to be important in the human diet, may play a key role in preventing osteoporosis, a debilitating bone condition that afflicts many older women, U.S. scientists reported in a paper to be published today. If confirmed by additional human studies, the finding may have broad implications because osteoporosis, or the loss of calcium from the bone, affects up to 20 million mostly post-menopausal women in the United States alone.
Los Angeles Times Articles